VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.45 Million in IDEAYA Biosciences, Inc. $IDYA

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 38,950 shares of the company’s stock, valued at approximately $1,452,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Royal Bank of Canada increased its position in IDEAYA Biosciences by 30.1% during the first quarter. Royal Bank of Canada now owns 122,460 shares of the company’s stock worth $2,006,000 after buying an additional 28,322 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of IDEAYA Biosciences by 8.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,044 shares of the company’s stock valued at $938,000 after buying an additional 4,308 shares during the last quarter. Millennium Management LLC boosted its stake in shares of IDEAYA Biosciences by 345.2% during the 1st quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock worth $8,970,000 after acquiring an additional 424,625 shares during the period. American Century Companies Inc. boosted its stake in shares of IDEAYA Biosciences by 862.7% during the 2nd quarter. American Century Companies Inc. now owns 114,644 shares of the company’s stock worth $2,410,000 after acquiring an additional 102,736 shares during the period. Finally, Norges Bank acquired a new position in shares of IDEAYA Biosciences during the 2nd quarter worth approximately $643,000. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Up 0.4%

NASDAQ IDYA opened at $37.59 on Friday. The company has a market capitalization of $3.30 billion, a P/E ratio of -19.38 and a beta of -0.07. IDEAYA Biosciences, Inc. has a 12-month low of $24.24 and a 12-month high of $42.68. The firm has a 50-day moving average price of $37.73 and a two-hundred day moving average price of $33.70.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.06) by ($0.16). IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The business had revenue of $8.86 million for the quarter, compared to the consensus estimate of $8.02 million. During the same period in the prior year, the business posted ($0.88) earnings per share. The firm’s revenue for the quarter was up 8800.0% compared to the same quarter last year. Equities analysts expect that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current year.

Insider Transactions at IDEAYA Biosciences

In other IDEAYA Biosciences news, CAO Andres Ruiz Briseno sold 9,550 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total transaction of $382,095.50. Following the transaction, the chief accounting officer owned 26,466 shares in the company, valued at $1,058,904.66. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.70% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on IDYA shares. Truist Financial dropped their price target on IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Friday, July 17th. Wedbush upped their price objective on shares of IDEAYA Biosciences from $58.00 to $60.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a research report on Friday, May 22nd. Finally, Wall Street Zen lowered shares of IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $52.69.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for cancer. The company uses insights from tumor genetics and synthetic lethality—the targeting of vulnerabilities created by specific genetic alterations—to identify therapies intended for molecularly defined patient populations.

IDEAYA’s investigational pipeline includes darovasertib (IDE196), a protein kinase C inhibitor being studied in genetically defined cancers, including metastatic uveal melanoma associated with GNAQ or GNA11 mutations.